Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1417380

DKRd (daratumumab, carfilzomib, lenalidomide, and dexamethasone) regimen in the treatment of newly diagnosed POEMS syndrome and literature review

Provisionally accepted
Jian chao Wang Jian chao Wang 1Wen sheng Liao Wen sheng Liao 1Zhong wen Liu Zhong wen Liu 2Dai Kong Dai Kong 2*
  • 1 Department of Surgery of Spine and Spinal Cord, Henan Provincial People’s Hospital, Zhengzhou, Henan Province, China
  • 2 Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China

The final, formatted version of the article will be published soon.

    POEMS syndrome, characterized as a rare multisystem paraneoplastic syndrome, arises from plasma cell abnormalities. Coined by Bardwick in 1980, the acronym POEMS delineates the distinctive features of the syndrome: Peripheral nerve Lesions, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes. The prevalence of POEMS syndrome stands at approximately 0.3 per 100,000 individuals . Owing to its low prevalence and the paucity of prospective studies, current treatment approaches largely hinge on retrospective studies and revolve around the use of plasma cell-directed therapy typically used in multiple myeloma treatments. This article presents the pioneering case of utilizing a four-drug combination regimen of DKRd (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as a first-line treatment. This is succeeded by induction therapy and subsequently, autologous hematopoietic stem cell transplantation. A comprehensive review of related literature is conducted.

    Keywords: POEMS Syndrome, Treatment, Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone

    Received: 14 Apr 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 Wang, Liao, Liu and Kong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dai Kong, Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, Henan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.